Slide 1: First Quarter 2019 Earnings Teleconference
First Quarter 2019 Earnings Teleconference April 30, 2019
Slide 2: Introduction
Introduction Chuck Triano Senior Vice President, Investor Relations First Quarter 2019 Earnings
Slide 3: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this conference call will include forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, expectations for in-line products a
Slide 4: Opening Remarks
Opening Remarks Albert Bourla Chief Executive Officer First Quarter 2019 Earnings
Slide 5: CEO Perspectives
CEO Perspectives Pleased to begin the year with a strong first quarter, with 5% operational revenue growth (+8% volume, -3% price) driven by volume growth in several key brands, emerging markets and biosimilars Pfizer Biopharmaceuticals Group grew revenues by 7% operationally (+11% volume, -3% p
Slide 6: Pfizer Pipeline Snapshot as of April 30, 2019
Pfizer Pipeline Snapshot as of April 30, 2019 Included are 54 NMEs, 39 additional indications, plus 4 biosimilars Recent Approvals • TRAZIMERA™ (trastuzumab-qyyp), a biosimilar to Herceptin®(1) (trastuzumab), for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast
Slide 7: Detailed Pipeline Snapshot: Phase 2 Through Registration
Detailed Pipeline Snapshot: Phase 2 Through Registration Phase 2 Phase 3 Registration Bavencio 1L Merkel Cell Carcinoma Bavencio 1L NSCLC Lorlatinib 2L ALK+ NSCLC (EU) Bavencio Combo w/PF-04518600 (OX40) - various solid tumors Bavencio 1L gastric cancer Biosimilar rituximab Follicular lymphoma (U.S.
Slide 8: Next Steps for 'Up to 15 in 5' Programs
Next Steps for 'Up to 15 in 5' Programs Up to 15 Potential Blockbusters Approved by 2022 (Subject to Attrition) THERAPEUTIC AREA PROGRAM NEXT STEP TIMING 1 I/O Mono / Chemo Combos Phase 3 pivotal readouts for Bavencio (1L gastric, 1L urothelial) 1H 2020 2 I/O-Targeted Agent Combos PDUFA June 2019
Slide 9: Next Generation Potential Breakthrough Treatments (Beyond "Up to 15 in 5")
Next Generation Potential Breakthrough Treatments* (Beyond "Up to 15 in 5") Targeting Cancer Advancing Bacterial, Modulating Cytokine Curing and Treating Treating Metabolic Vulnerabilities and Maternal & Cancer Pathways Rare Diseases Dysfunction Resistance Vaccines Xtandi + Talzenna 20v Next Generat
Slide 10: Financial Review
Financial Review Frank D’Amelio Chief Financial Officer and Executive Vice President, Business Operations & Global Supply First Quarter 2019 Earnings
Slide 11: Income Statement Highlights
Income Statement Highlights ($ Millions, Except Per Share Amounts and Percentages) First Quarter 2019 2018 Change Revenues $13,118 $12,906 2% Reported Net Income(1) 3,884 3,561 9% Reported Diluted EPS(1) 0.68 0.59 15% Adjusted Income(1) 4,891 4,555 7% Adjusted Diluted EPS(1) 0.85 0.75 13% Q1 2019 Re
Slide 12: Impact of Foreign Exchange on Revenues and Select Adjusted Income Components
Impact of Foreign Exchange on Revenues and Select Adjusted Income(1) Components ($ Millions, Except Percentages) Favorable / (Unfavorable) First Quarter 2019 2018 FX Impact Revenues $13,118 $12,906 ($453) (4%) Adjusted Cost of Sales(1) 2,415 2,536 211 8% COS as a Percentage of Revenues 18.4% 19.7% 0
Slide 13: 2019 Financial Guidance
2019 Financial Guidance(1) Revenues $52.0 to $54.0 billion Adjusted Cost of Sales(1) as a Percentage of Revenues 20.8% to 21.8% Adjusted SI&A Expenses(1) $13.5 to $14.5 billion Adjusted R&D Expenses(1) $7.8 to $8.3 billion Approximately $200 million of income Adjusted Other (Income)/Deductions(1) (p
Slide 14: Key Takeaways
Key Takeaways Delivered strong quarterly financial results, with 5% operational Revenue growth and 13% Adjusted diluted EPS(1) growth compared to the same period last year Raised our 2019 financial guidance range for Adjusted diluted EPS(1) by $0.01, reflecting a $0.03 operational improvement, parti
Slide 15: First Quarter 2019 Earnings Teleconference Q&A Session
First Quarter 2019 Earnings Teleconference Q&A Session April 30, 2019
Slide 16: Footnotes
Footnotes Financial Definitions Footnotes (1) Reported net income is defined as net income attributable to Pfizer Inc. in accordance with U.S. GAAP. Reported diluted earnings per share (EPS) are defined as diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP. (2)